Navigation Links
Semafore to Present at BIO CEO & Investor Conference

INDIANAPOLIS, Feb. 8 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that Edward L. Jacobs, president and chief executive officer, and Ullrich Schwertschlag, M.D., Ph.D., chief medical officer, will present an update of the company's product development programs at 2:45 p.m. EST on Wednesday, Feb. 13, 2008, at the BIO CEO & Investor Conference in New York City.

The update will include information about Semafore's lead product candidate, SF1126, a targeted PI3 kinase inhibitor currently in Phase 1 clinical trials in solid tumors and multiple myeloma. The presentation will also include a review of the company's pipeline advancements and business development initiatives.

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's Web site at


Corporate Media

Semafore Pharmaceuticals Inc. Russo Partners LLC

Bob Marshall or Ed Jacobs David Schull or Timothy Engel

(480) 278-8200 (212) 845-4271

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Genomic Health to Present at BIO CEO & Investor Conference
3. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
4. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
5. Avicena Group to Present at 10th Annual BIO CEO & Investor Conference
6. Micromet to Present at Two Upcoming Investor Conferences
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Genelabs Technologies to Present at the BIO CEO & Investor Conference
9. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... ...
Breaking Biology News(10 mins):